drugset / Trial / NCT04522622
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
Phase 4
Recruiting
48 enrolled
Ditte Hansen
Aalborg University Hospital · collabOdense University Hospital · collabRigshospitalet, Denmark · collabSteno Diabetes Center Copenhagen · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for treatment of adynamic bone disorder in patients with chronic kidney disease.
Timeline
- Start
- 2021-12-15
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teriparatide | Protein / enzyme biologic | 20 ug | — |